围术期使用肾素-血管紧张素系统抑制剂对冠状动脉旁路移植术患者肾功能及临床结局的影响
该研究为回顾性队列分析,基于中国医学科学院阜外医院2013年1月至2022年12月接受CABG的成年患者注册数据,纳入33 884例,平均随访(3.0±2.4)年,最长8.5年。术前48小时内使用RASi(PreRASi)组9 128例(26.94%),未使用组24 756例(73.06%)。主要终点术后AKI发生率在PreRASi组为47.61%(4 346例),No-PreRASi组为52.37%(12 964例);倾向性评分匹配(PSM)前后PreRASi均与术后AKI风险降低相关(匹配前OR=0.834,95%CI 0.793-0.877,P<0.001;匹配后OR=0.875,95%CI 0.808-0.948,P=0.001),高血压和HFpEF亚组结果一致。院内死亡率两组分别为0.61%(56例)和0.49%(121例),PreRASi与院内死亡及最长随访期死亡均无相关性。结论提示围术期使用RASi可能具有肾脏保护作用,但不影响短期或远期死亡风险。
要点
- 在CABG患者中,术前48小时内使用RASi与术后AKI风险降低独立相关:PSM前OR=0.834(95%CI 0.793-0.877,P<0.001),PSM后OR=0.875(95%CI 0.808-0.948,P=0.001)。
- 高血压及HFpEF亚组分析显示,PSM前后PreRASi均与术后AKI风险降低相关。
- PreRASi组与No-PreRASi组院内死亡率分别为0.61%(56例)和0.49%(121例),总体队列及高血压、HFpEF亚组均未显示PreRASi与院内死亡或最长随访期死亡相关。
- 该研究为单中心回顾性队列,纳入33 884例CABG患者,平均随访(3.0±2.4)年,最长8.5年。
- 术后AKI采用KDIGO诊断标准定义。
适用人群与场景
- 中国医学科学院阜外医院2013年1月至2022年12月接受CABG的成年患者,基于注册研究数据。
- 根据术前48小时内是否接受RASi治疗分为PreRASi组(9 128例,26.94%)和No-PreRASi组(24 756例,73.06%)。
- 亚组分析纳入高血压患者和射血分数保留的心力衰竭(HFpEF)患者。
诊断标准与关键阈值
- 术前使用RASi(PreRASi)定义为术前48小时内接受RASi治疗。
- 术后急性肾损伤(AKI)采用改善全球肾脏病预后组织(KDIGO)诊断标准定义。
研究设计与关键结果
- 研究类型为回顾性队列分析,基于单中心注册数据,共纳入33 884例CABG患者,平均随访(3.0±2.4)年,最长随访8.5年。
- 主要终点术后AKI发生率:PreRASi组47.61%(4 346例) vs No-PreRASi组52.37%(12 964例)。
- 倾向性评分匹配(PSM)后两组各5 094例;PSM前PreRASi与术后AKI风险降低相关(OR=0.834,95%CI 0.793-0.877,P<0.001),PSM后仍相关(OR=0.875,95%CI 0.808-0.948,P=0.001)。
- 高血压和HFpEF亚组分析显示,PSM前后PreRASi均与术后AKI风险降低相关。
- 院内死亡率:PreRASi组0.61%(56例) vs No-PreRASi组0.49%(121例);总体队列及高血压、HFpEF亚组分析均未显示PreRASi与院内死亡或最长随访期死亡相关。
证据类型、等级与局限
- 证据类型:回顾性队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,围术期使用RASi可降低CABG患者术后AKI风险,具有一定肾脏保护作用,但与术后短期或长期死亡风险无关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the effects of preoperative renin-angiotensin system inhibitor (RASi) use on postoperative renal function and short-term and long-term prognosis in patients undergoing coronary artery bypass grafting (CABG).
METHODS: A retrospective cohort analysis was conducted. Based on the registration study data of CABG patients at Fuwai Hospital, Chinese Academy of Medical Sciences, the clinical data of adult patients who underwent CABG from January 2013 to December 2022 were analyzed. Preoperative use of RASi (PreRASi) was defined as receiving RASi treatment within 48 hours before surgery. Postoperative acute kidney injury (AKI) was defined using the diagnostic criteria of Kidney Disease: Improving Global Outcomes (KDIGO). Demographic characteristics, past medical history, comorbidities, preoperative medication, preoperative laboratory test results, specific information on surgical procedures, and postoperative treatment related data were extracted. The primary endpoint was the incidence of postoperative AKI. Secondary endpoints included in-hospital all-cause mortality and all-cause mortality within the longest follow-up period. According to whether RASi was used before surgery, the patients were divided into PreRASi group and No-PreRASi group. The baseline data of the two groups were balanced by propensity score matching (PSM). Logistic regression model and Cox proportional hazards model were used to assess the correlation between PreRASi and postoperative AKI and clinical outcomes, and analyze the subgroups of hypertension and heart failure with preserved ejection fraction (HFpEF) in the cohort.
RESULTS: A total of 33 884 patients who underwent CABG were included, with a mean follow-up duration of (3.0±2.4) years and the longest follow-up duration up to 8.5 years. There were 9 128 cases (26.94%) in the PreRASi group and 24 756 cases (73.06%) in the No-PreRASi group. The incidence of postoperative AKI in the PreRASi group was 47.61% (4 346 cases), compared to 52.37% (12 964 cases) in the No-PreRASi group. Two groups were matched with 5 094 patients each. Compared to the No-PreRASi group, both before and after PSM, PreRASi was associated with a reduction of risk of postoperative AKI [before PSM: odds ratio (OR) = 0.834, 95% confidence interval (95%CI) was 0.793-0.877, P < 0.001; after PSM: OR = 0.875, 95%CI was 0.808-0.948, P = 0.001]. Subgroup analysis of hypertensive and HFpEF patients showed that PreRASi was associated with a decreased risk of postoperative AKI before and after PSM. The in-hospital mortality for the PreRASi and No-PreRASi groups were 0.61% (56 cases) and 0.49% (121 cases), respectively. Analysis of the overall cohort and subgroups with hypertension and HFpEF showed no correlation between PreRASi and in-hospital mortality or longest follow-up mortality.
CONCLUSIONS: The perioperative use of RASi can reduce the risk of postoperative AKI in patients undergoing CABG, has a certain renal protective effect, but is not associated with short-term or long-term death risk after surgery.
参考来源
- Zhou H, Su X, Zhang H, et al. [Effects of perioperative use of renin-angiotensin system inhibitor on renal function and clinical outcomes in patients undergoing coronary artery bypass grafting surgery]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39586724. doi:10.3760/cma.j.cn121430-20240801-00652
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。